Abstract
CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. We performed a randomized phase II study to explore a more promising schedule in untreated, advanced indolent B-NHL. Patients were randomized to receive either six courses of CHOP concurrently with rituximab (Arm C), or six courses of CHOP followed by six courses of weekly rituximab (Arm S). A total of 69 patients received the concurrent (n=34) or sequential (n=35) regimen. Overall response rate (ORR) in Arm C was 94% (95% confidence interval [CI], 79 to 99), including a 66% complete response (CR) compared with 97% (95% CI, 85-100), including a 68% CR in Arm S. Patients in Arm C experienced more grade 4 neutropenia (85%versus 70%) and experienced more grade 3 or greater non-hematological toxicities (21%versus 12%). Both arms were tolerated well. With a median follow-up of 28.2 months, the median progression-free survival (PFS) time was 34.2 months in Arm C, and was not reached in Arm S. R-CHOP is highly effective in untreated indolent B-NHL, either concurrent or in a sequential combination. Both combination schedules deserve further...Continue Reading
References
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E KimbyE Löfvenberg
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C Aisenberg
Dec 1, 1994·Histopathology·J K ChanP G Isaacson
Dec 1, 1994·Blood Reviews·W Hiddemann, M Unterhalt
Mar 15, 1994·Statistics in Medicine·R SimonS S Ellenberg
May 1, 1997·Diabetes Care·C M ClarkA Golichowski
Dec 1, 1996·Baillière's Clinical Haematology·P Solal-Celigny
Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Jul 8, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TobinaiT Murate
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Sep 17, 1998·Japanese Journal of Cancer Research : Gann·H TajiY Morishima
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanC Varns
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jun 10, 2000·British Journal of Haematology·J M ForanT A Lister
Jun 1, 1997·Cancer Biotherapy & Radiopharmaceuticals·A DemidemB Bonavida
Jan 3, 2001·Blood·P ColombatP Solal-Céligny
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T IgarashiUNKNOWN IDEC-C2B8 Study Group in Japan
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Oct 24, 2002·Blood·John C ByrdRichard A Larson
Feb 21, 2004·Blood·Michele GhielminiThomas Cerny
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Jul 31, 2004·Blood·Roswitha ForstpointnerUNKNOWN German Low-Grade Lymphoma Study Group
Oct 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanAntonio J Grillo-López
Oct 21, 2004·Blood·Robert MarcusPaul Smith
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S CzuczmanS H Bernstein
Citations
Jan 13, 2010·International Journal of Hematology·Ritsuko SekiTakashi Okamura
Sep 3, 2008·The Journal of Laryngology and Otology·F O AgadaJ Greenman
Jun 25, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake
Aug 31, 2007·Journal of the National Cancer Institute·Olaf WeingartAndreas Engert
Oct 25, 2011·Journal of the National Cancer Institute·Liat VidalOfer Shpilberg
Jan 16, 2007·Internal Medicine·Kensei Tobinai
May 18, 2007·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Michinori Ogura
Nov 4, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiM Tanimoto
Apr 23, 2013·Expert Opinion on Biological Therapy·Edward M VitalPaul Emery
Nov 21, 2009·Archives of Gerontology and Geriatrics·Kazuyoshi IshiiShosaku Nomura
Feb 9, 2007·Critical Reviews in Oncology/hematology·Guillaume CartronChantal Le Guellec
Jul 15, 2009·Cancer Science·Kensei TobinaiTomomitsu Hotta
Nov 21, 2008·Cancer Science·Kensei TobinaiKeigo Endo
Jan 6, 2011·Cancer Science·Kensei TobinaiMinori Koshiji
Oct 15, 2010·Cancer Science·Kensei TobinaiUNKNOWN All Collaborators of the IDEC-C2B8 Study Group in Japan
Mar 3, 2010·American Journal of Hematology·Rebecca L OlinCharalambos Andreadis
Oct 8, 2016·International Journal of Hematology·Tadahiko IgarashiKensei Tobinai
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Jasvinder A SinghRachelle Buchbinder
Oct 19, 2007·The Cochrane Database of Systematic Reviews·H SchulzA Engert
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Liat VidalOfer Shpilberg
Dec 3, 2016·International Journal of Hematology·Michinori OguraUNKNOWN Japanese Bendamustine Lymphoma Study Group
Feb 23, 2017·The AAPS Journal·Rui ZhuJin Yan Jin